Seminars in Oncology
Volume 32, Issue 2 , Pages 200-210 , April 2005

Control of common, non-pain cancer symptoms

  • Jamie H. Von Roenn

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jamie H. Von Roenn, MD, Professor of Medicine, Division of Hematology/Oncology, The Feinberg School of Medicine, Northwestern University, 676 North St. Clair St, Ste 850, Chicago, IL 60611
    • ,
  • Judith A. Paice

References 

  1. Irvine D , Vincent L , Graydon JE , et al.   The prevalence and correlates of fatigue in patients receiving chemotherapy and radiotherapy (A comparison with the fatigue experienced by healthy individuals) . Cancer Nurs . 1994;17:367–378
  2. Haylock PJ , Hart LK . Fatigue in patients receiving localized radiation . Cancer Nurs . 1979;2:461–467
  3. Greenberg DB , Sawicka J , Eisenthal S , et al.   Fatigue syndrome due to localized radiation . J Pain Symptom Manage . 1992;7:38–45
  4. Vogelzang N , Breitbart W , Cella D , et al.   Patient, caregiver, and oncologist perceptions of cancer-related fatigue (Results of a tri-part assessment survey) . Semin Hematol . 1997;34(suppl 2):4–12
  5. Cella D , Peterman A , Passik S , et al.   Progress toward guidelines for the management of fatigue . Oncology . 1998;12:369–377
  6. Stone P , Richardson A , Ream E , et al.   Cancer-related fatigue: Inevitable, unimportant and untreatable?: Results of a multi-centre patient survey . Ann Oncol . 2000;11:971–975
  7. Dean GE , Spears L , Ferrell BR , et al.   Fatigue in patients with cancer receiving interferon alpha . Cancer Pract . 1995;3:164–172
  8. Piper BF , Rieger PT , Brophy L , et al.   Recent advances in the management of biotherapy-related side effects (Fatigue) . Oncol Nurs Forum . 1989;16(suppl 6):27–34
  9. Schwartz AL , Nail LM , Chen S , et al.   Fatigue patterns observed in patients receiving chemotherapy and radiotherapy . Cancer Invest . 2000;18:11–19
  10. Richardson A , Ream E , Wilson-Barnett J . Fatigue in patients receiving chemotherapy (Patterns of change) . Cancer Nurs . 1998;21:17–30
  11. Irvine DM , Vincent L , Graydon JE , et al.   Fatigue in women with breast cancer receiving radiation therapy . Cancer Nurs . 1998;21:127–135
  12. Smets EMA , Garssen B , Schuster-Uitterhove ALJ , et al.   Fatigue in cancer patients . Br J Cancer . 1993;68:220–224
  13. Berglund G , Bolund C , Fornander T , et al.   Late effects of adjuvant chemotherapy and post-operative radiotherapy on quality of life among breast cancer patients . Eur J Cancer Care . 1991;27:1075–1081
  14. Portenoy RK , Itri LM . Cancer-related fatigue (Guidelines for evaluation and management) . Oncologist . 1999;4:1–10
  15. Weber J , Yang JC , Topalian SL , et al.   Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies . J Clin Oncol . 1993;11:499–506
  16. Gordon MS , Nemunaitis J , Hoffman R , et al.   A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia . Blood . 1995;85:3066–3076
  17. Mock V , Atkinson A , Barsevick A , et al.   Cancer-Related Fatigue Guidelines . NCCN Practice Guidelines in Oncology – v.1.2003 . Jenkintown, PA: National Comprehensive Cancer Network; 2003;
  18. Johnson JE . Self-regulation theory and coping with physical illness . Res Nurs Health . 1999;22:435–448
  19. Morrow GR , Hickok JT , Raubertas RF , et al.   Effect of an SSRI antidepressant on fatigue and depression in 738 cancer patients treated with chemotherapy (A URCC CCOP study) . Proc Am Soc Clin Oncol . 2001;20:384a; (abstr 1531)
  20. Glaspy JA , Jadeja JS , Justice G , et al.   A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease . Cancer . 2003;97:1312–1320
  21. Quirt I , Robeson C , Lau CY , et al.   Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy . J Clin Oncol . 2001;19:4126–4134
  22. Rizzo JD , Lichtin AE , Woolf SH , et al.   Use of epoetin in patients with cancer (Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology) . J Clin Oncol . 2002;20:4083–4107
  23. Crawford J , Cella D , Cleeland CS , et al.   Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy . Cancer . 2002;95:888–895
  24. Chang J , Couture F . Once weekly epoetin alfa maintains hemoglobin, improves quality of life and reduces transfusion in breast cancer patients receiving chemotherapy . Proc Am Soc Clin Oncol . 2003;22:727; (abstr 2923)
  25. Vadhan-Raj S , Schreiber F , Thomas LC , et al.   Every-2-week darbepoetin alfa improves fatigue and energy rating scores in cancer patients undergoing chemotherapy . Proc Am Soc Clin Oncol . 2003;22:732; (abstr 2942)
  26. Mirtsching BC , Beck JT , Charu V , et al.   Darbepoetin alfa administered every two weeks reduces chemotherapy-induced anemia to the same extent as recombinant human erythropoietin but with less-frequent dosing . Proc Am Soc Clin Oncol . 2003;22:732; (abstr 2944)
  27. Schwartzberg L , Hesketh P , Rossi G , et al.   Optimizing management of chemotherapy-induced anemia (A combined analysis of data using a darbepoetin alfa frontloading/maintenance approach) . Proc Am Soc Clin Oncol . 2003;22:732; (abstr 2945)
  28. Crews DJ , Landers DM . A meta-analytic review of aerobic fitness and reactivity to psychosocial stressors . Med Sci Sports Exerc . 1987;19:5114–5120
  29. Winningham ML , MacVicar MG , Dondoc M , et al.   Effect of aerobic exercise on body weight and composition in patients with breast cancer on adjuvant chemotherapy . Oncol Nurs Forum . 1989;16:685–689
  30. MacVicar SB , Winningham ML . Promoting the functional capacity of cancer patients . Cancer Bull . 1986;38:235–239
  31. Mock V , Burke MB , Sheehan PK , et al.   A nursing rehabilitation program for women with breast cancer receiving adjuvant chemotherapy . Oncol Nurs Forum . 1994;21:899–908
  32. Dimeo FC , Stieglitz RD , Novelli-Fischer U , et al.   Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy . Cancer . 1999;85:2273–2277
  33. Schwartz AL . Daily fatigue patterns and effect of exercise in women with breast cancer . Cancer Prac . 2000;8:16–24
  34. Dimeo FC , Tilmann MH , Bertz H , et al.   Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation . Cancer . 1997;79:1717–1722
  35. Winningham ML , Burke C . Exercise for cancer patients (Guidelines and precautions) . Phys Sports Med . 1986;14:125–131
  36. Fatigue (Optimizing Cancer Care—The Importance of Symptom Management) . Vol I.. Alexandria, VA: American Society of Clinical Oncology; 2003;
  37. Breitbart W , Rosenfeld B , Kaim M , et al.   A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease . Arch Intern Med . 2001;161:411–420
  38. Hanna AR , Gledge GW , Mayer ML , et al.   Preliminary results of a phase II trial of methylphenidate in patients with breast carcinoma . Proc Am Soc Clin Oncol . 2003;22:727; (abstr 2922)
  39. Sarhill N , Walsh D , Nelson KA , et al.   Methylphenidate for fatigue in advanced cancer (A prospective open-label pilot study) . Am J Hosp Palliat Care . 2001;18:187–192
  40. Schwartz AL , Thompson JA , Masood N . Interferon-induced fatigue in patients with melanoma (A pilot study of exercise and methylphenidate) . Oncol Nurs Forum . 2002;29:E85–E90
  41. Bruera E , Driver L , Barnes EA , et al.   Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer (A preliminary report) . J Clin Oncol . 2003;21:4439–4443
  42. Tannock J , Gospodarowicz M , Meakin W , et al.   Treatment of metastatic prostatic cancer with low-dose prednisone (Evaluation of pain and quality of life as pragmatic indices of response) . J Clin Oncol . 1989;7:590–597
  43. Rammohan KW , Rosenberg JH , Lynn DJ , et al.   Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis (A two centre phase 2 study) . J Neurol Neurosurg Psychiatry . 2002;72:179–183
  44. DeWys WD , Begg C , Lavin PT , et al.   Prognostic effect of weight loss prior to chemotherapy in cancer patients . Am J Med . 1980;69:491–497
  45. Ottery F , Kasenic S , DeBolt S , et al.  Presented at the Annual Meeting of the American Society of Clinical Oncology   Volunteer network accrues >1900 patients in 6 months to validate standardized nutritional triage . 1998; Los Angeles, CA, May 16–19
  46. Bhasin S , Storer TW , Berman N , et al.   Testosterone replacement increases fat-free mass and muscle size in hypogonadal men . J Clin Endocrinol Metab . 1997;82:407–413
  47. Loprinzi CL , Ellison NM , Schaid DJ , et al.   Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia . J Natl Cancer Inst . 1990;82:1127–1132
  48. Bruera E , MacMillan K , Kuehn N , et al.   A controlled trial of megestrol acetate on appetite, calorie intake, nutritional status and other symptoms in patients with advanced cancer . Cancer . 1990;66:1279–1282
  49. Loprinzi CL , Michalak JC , Schaid DJ , et al.   Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia . J Clin Oncol . 1993;11:762–767
  50. Loprinzi CL , Schaid DJ , Dose AM , et al.   Body-composition changes in patients who gain weight while receiving megestrol acetate . J Clin Oncol . 1993;11:152–154
  51. Mann M , Koller E , Murgo A , et al.   Glucocorticoidlike activity of megestrol . Arch Intern Med . 1997;157:1651–1656
  52. Loprinzi CL , Jensen MD , Jiang NS , et al.   Effect of megestrol acetate on the human pituitary-adrenal axis . Mayo Clin Proc . 1992;67:1160–1162
  53. Lang I , Zielinski CC , Templ H , et al.   Medroxyprogesterone acetate lowers plasma corticotropin and cortisol but does not suppress anterior pituitary responsiveness to human corticotropin releasing factor . Cancer . 1990;66:1949–1953
  54. Engelson ES , Pi-Sunyer FX , Kotler DP . Effects of megestrol acetate therapy on body composition and circulating testosterone concentration in patients with AIDS . AIDS . 1995;9:1107–1108
  55. Beal JE , Olson R , Laubenstein L , et al.   Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS . J Pain Symptom Manage . 1995;10:89–97
  56. Nelson K , Walsh D , Deeter P , et al.   A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia . J Palliat Care . 1994;10:14–18
  57. Jatoi A , Windschitl HE , Loprinzi CL , et al.   Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia (A North Central Cancer Treatment Group study) . J Clin Oncol . 2002;20:567–573
  58. Moertel C , Schulte A , Reitemeier R . Corticosteroid therapy of preterminal gastrointestinal cancer . Cancer . 1974;33:1607–1609
  59. Willox JC , Corr J , Shaw J . Prednisone as an appetite stimulant in patients with cancer . Br Med J Clin . 1984;288:27; Res Ed
  60. Bruera E , Roca E , Cedaro L , et al.   Action of oral methylprednisolone in terminal cancer patients (A prospective randomized double-blind study) . Cancer Treat Rep . 1985;69:751–754
  61. Della Cuna GR , Pellegrini A , Piazzi M . Effect of methylprednisolone sodium succinate on quality of life in pre-terminal cancer patients (A placebo controlled, multi-center study) . Eur J Cancer Clin Oncol . 1989;25:1817–1821
  62. Popiela T , Lucchi R , Giongo F . Methylprednisolone as palliative therapy for female terminal cancer patients . Eur J Cancer Clin Oncol . 1989;25:1923–1929
  63. Stiefel FC , Breitbart WS , Holland JC . Corticosteroids in cancer (Neuropsychiatric complications) . Cancer Invest . 1989;7:479–491
  64. Chlebowski RT , Herrold J , Ali I , et al.   Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer . Cancer . 1986;58:183–186
  65. Von Roenn JH , Tchekmedyian S , Ottery F  Supportive Cancer in Cancer at the combined meeting of The Multinational Association of Supportive Care in Cancer and The International Society of Oral Oncology . Oxandrolone increases weight, lean tissue, performance status and quality of life (QOL) scores in cancer-related weight loss . 14th International Symposium . 2002; Boston, MA, June 23–26 (poster 114)
  66. Tchekmedyian S , Thropay J , Von Roenn J , et al.  Annual Meeting of the American Society of Therapeutic Radiology and Oncology   Patients with aerodigestive tract cancer and pre-existing weight loss (Performance status, quality of life, and laboratory parameters with oxandrolone use) . 2002; New Orleans, LA, October 6–10, (poster 2176)
  67. Stuart CA , Shangraw RE , Prince MJ , et al.   Bed rest induced insulin resistance occurs primarily in muscle . Metabolism . 1988;37:802–806
  68. Shangraw RE , Stuart CA , Prince MJ , et al.   Insulin responsiveness of protein metabolism in vivo following bed rest in humans . Am J Physiol . 1988;255:E4548–E4558
  69. Evans WJ , Roubenoff R , Schevitz A . Exercise and the treatment of wasting (Aging and human immunodeficiency virus infection) . Semin Oncol . 1998;25:112–122
  70. Bruera E , Strasser F , Palmer JL , et al.   Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia (A double-blind, placebo-controlled study) . J Clin Oncol . 2003;21:129–134
  71. Barber MD , Ross JA , Voss AC , et al.   The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer . Br J Cancer . 1999;81:80–86
  72. Wigmore SJ , Barber MD , Ross JA , et al.   Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer . Nutr Cancer . 2000;36:177–184
  73. Burns CP , Halabi S , Clamon GH , et al.   Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia (Cancer and Leukemia Group B Study 9743) . Clin Cancer Res . 1999;5:3942–3947
  74. Reyes-Teran G , Sierra-Madero JG , Martinez del Cerro V , et al.   Effect of thalidomide on HIV associated wasting syndrome (A randomized double-blind, placebo-controlled clinical trial) . AIDS . 1996;10:1501–1507
  75. Bruera E , Schmitz B , Pither J , et al.   The frequency and correlates of dyspnea in patients with advanced cancer . J Pain Symptom Manage . 2000;19:357–362
  76. Potter J , Hami F , Bryan T , et al.   Symptoms in 400 patients referred to palliative care services (Prevalence and patterns) . Palliat Med . 2003;17:310–314
  77. Wolfe J , Grier HE , Klar N , et al.   Symptoms and suffering at the end of life in children with cancer . N Engl J Med . 2000;342:326–333
  78. Bruera E , Sweeney C , Willey J , et al.   A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea . Palliat Med . 2003;17:659–663
  79. Escalante CP , Martin CG , Elting LS , et al.   Dyspnea in cancer patients (Etiology, resource utilization, and survival-implications in a managed care world) . Cancer . 1996;78:1314–1319
  80. Escalante CP , Martin CG , Elting LE , et al.   Identifying risk factors for imminent death in cancer patients with acute dyspnea . J Pain Symptom Manage . 2000;20:318–325
  81. Reuben DB , Mor V . Dyspnea in terminally ill cancer patients . Chest . 1986;89:234–236
  82. Ripamonti C . Management of dyspnea in advanced cancer patients . Support Care Cancer . 1999;7:233–243
  83. O’Driscoll M , Corner J , Bailey C . The experience of breathlessness in lung cancer . Eur J Cancer Care . 1999;8:37–43
  84. Thomas JR , von Gunten CF . Management of dyspnea . J Support Oncol . 2003;1:23–34
  85. Dudgeon DJ , Kristjanson L , Sloan JA , et al.   Dyspnea in cancer patients (Prevalence and associated factors) . J Pain Symptom Manage . 2001;21:95–102
  86. Mosenthal AC , Lee KF . Management of dyspnea at the end of life (Relief for patients and surgeons) . J Am Coll Surg . 2002;194:377–386
  87. Jennings AL, Davies AN, Higgins JP, et al: Opioids for the palliation of breathlessness in terminal illness. Cochrane Database of Systemic Reviews 4:CD002066
  88. LeGrand SB , Khawam EA , Walsh D , et al.   Opioids, respiratory function, and dyspnea . Am J Hosp Palliat Care . 2003;20:57–61
  89. Bruera E , MacEachern T , Ripamonti C , et al.   Subcutaneous morphine for dyspnea in cancer patients . Ann Intern Med . 1993;119:906–907
  90. Thomas JR , von Gunten CF . Clinical management of dyspnoea . Lancet Oncol . 2002;3:223–228
  91. Zebraski SE , Kochenash SM , Raffa RB . Lung opioid receptors (Pharmacology and possible target for nebulized morphine in dyspnea) . Life Sci . 2000;66:2221–2231
  92. Farncombe M , Chater S , Gillin A . The use of nebulized opioids for breathlessness (A chart review) . Palliat Med . 1994;8:306–312
  93. Foral PA , Malesker MA , Huerta G , et al.   Nebulized opioid use in COPD . Chest . 2004;125:691–694
  94. Coyne PJ , Viswanathan R , Smith TJ . Nebulized fentanyl citrate improves patients’ perception of breathing, respiratory rate, and oxygen saturation in dyspnea . J Pain Symptom Manage . 2002;23:157–160
  95. Booth S , Wade R . Oxygen or air for palliation of breathlessness in advanced cancer . J R Soc Med . 2003;96:215–218
  96. Bredin M , Corner J , Krishnasamy M , et al.   Multicentre randomized controlled trial of nursing intervention for breathlessness in patients with lung cancer . BMJ . 1999;318:901–904
  97. Pan CX , Morrison RS , Ness J , et al.   Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life (A systemic review) . J Pain Symptom Manage . 2000;20:374–387
  98. Brubacher S , Gobel BH . Use of the Pleurx Pleural Catheter for the management of malignant pleural effusions . Clin J Oncol Nurs . 2003;7:35–38
  99. Braun TC , Hagen NA , Clark T . Development of a clinical practice guideline for palliative sedation . J Palliat Med . 2003;6:345–350
  100. Gregory RE , Grossman S , Sheidler VR . Grand mal seizures associated with high-dose intravenous morphine infusions (Incidence and possible etiology) . Pain . 1992;51:255–258
  101. Hagen N , Swanson R . Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration (Treatment strategies) . J Pain Symptom Manage . 1997;14:51–58
  102. Mercadante S . Pathophysiology and treatment of opioid-related myoclonus in cancer patients . Pain . 1998;74:5–9
  103. Smith MT . Neuroexcitatory effects of morphine and hydromorphone (Evidence implicating the 3-glucuronide metabolites) . Clin Exp Pharmacol Physiol . 2000;27:524–528
  104. Babul N , Darke AC , Hagen N . Hydromorphone metabolite accumulation in renal failure . J Pain Symptom Manage . 1995;10:184–186
  105. Fainsinger R , Schoeller T , Boiskin M , et al.   Palliative care round (Cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone) . J Palliat Care . 1993;9:53–55
  106. Sjogren P , Thunedborg LP , Christrup L , et al.   Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? (Six case histories) . Acta Anaesthesiol Scand . 1998;42:1070–1075
  107. Lee MA , Leng ME , Tiernan EJ . Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine . Palliat Med . 2001;15:26–34
  108. Sarhill N , Davis MP , Walsh D , et al.   Methadone-induced myoclonus in advanced cancer . Am J Hosp Palliat Care . 2001;18:51–53
  109. Adair JC , el-Nachef A , Cutler P . Fentanyl neurotoxicity . Am Emerg Med . 1996;27:791–792
  110. Bruera E , Pereira J . Actue neuropsychiatric findings in a patient receiving fentanyl for cancer pain . Pain . 1997;69:199–201
  111. Han PK , Arnold R , Bond G , et al.   Myoclonus secondary to withdrawal from transdermal fentanyl (Case report and literature review) . J Pain Symptom Manage . 2002;23:66–72
  112. Nishigaya K , Kaneko M , Nagaseki Y , et al.   Palatal myoclonus induced by extirpation of a cerebellar astrocytoma (Case report) . J Neurosurg . 1998;88:1107–1110
  113. Ford B , Pullman SL , Khandji A , et al.   Spinal myoclonus induced by an intrathecal catheter . Mov Disord . 1997;12:1042–1045
  114. Maher J , Choudhri S , Halliday W , et al.   AIDS dementia complex with generalized myoclonus . Mov Disord . 1997;12:593–597
  115. Werhahn KJ , Brown P , Thompson PD , et al.   The clinical features and prognosis of chronic posthypoxic myoclonus . Mov Disord . 1997;12:216–220
  116. Wyllie AR , Bayliff CD , Kovacs MJ . Myoclonus due to chlorambucil in two adults with lymphoma . Ann Pharmacother . 1997;31:171–174
  117. Pranzatelli MR . The immunopharmacology of opsoclonus-myoclonus syndrome . Clin Neuropharmacol . 1996;19:1–47
  118. Pranzatelli MR , Tate ED , Kinsbourne M , et al.   Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia (Cerebellar atrophy, multiphasic relapses, and response to IVIG) . Mov Disord . 2002;17:1387–1390
  119. Batchelor TT , Platten M , Hochberg FH . Immunoabsorption therapy for paraneoplastic syndromes . J Neurooncol . 1998;40:131–136
  120. Cherny N , Ripamonti C , Pereira J , et al.   Strategies to manage the adverse effects of oral morphine (An evidence-based report) . J Clin Oncol . 2001;19:2542–2554
  121. Eisele JH , Grigsby EJ , Dea G . Clonazepam treatment of myoclonic contractions associated with high-dose opioids (Case report) . Pain . 1992;49:231–232
  122. Mercadante S . Dantrolene treatment of opioid-induced myoclonus . Anesth Analg . 1995;81:1307–1308
  123. Stayer C , Tronnier V , Dressnandt J , et al.   Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalomyelopathy with rigidity and myoclonus . Neurology . 1997;49:1591–1597
  124. Morita T , Ichiki T , Tsunoda J , et al.   A prospective study on the dying process in terminally ill cancer patients . Am J Hosp Palliat Care . 1998;15:217–222
  125. Wildiers H , Menten J . Death rattle (Prevalence, prevention and treatment) . J Pain Symptom Manage . 2002;23:310–317
  126. Kass RM , Ellershaw J . Respiratory tract secretions in the dying patient (A retrospective study) . J Pain Symptom Manage . 2003;26:897–902
  127. Bennett M , Lucas V , Brennan M , et al.   Using anti-muscarinic drugs in the management of death rattle (Evidence-based guidelines for palliative care) . Palliat Med . 2002;16:369–374
  128. Morita T , Tsunoda J , Inoue S , et al.   Contributing factors to physical symptoms in terminally ill cancer patients . J Pain Symptom Manage . 1999;18:338–346
  129. Morita T , Tsunoda J , Inoue S , et al.   Risk factors for death rattle in terminally ill cancer patients (A prospective exploratory study) . Palliat Med . 2000;14:19–23
  130. Bennett MI . Death rattle (An audit of hyoscine (scopolamine) use and review of management) . J Pain Symptom Manage . 1996;12:229–233
  131. Back IN , Jenkins K , Blower A , et al.   A study comparing hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle . Palliat Med . 2001;15:329–336

PII: S0093-7754(04)00577-9

doi: 10.1053/j.seminoncol.2004.11.019

Seminars in Oncology
Volume 32, Issue 2 , Pages 200-210 , April 2005

Article Tools